Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Naptumomab estafenatox |
Synonyms | |
Therapy Description |
Naptumomab estafenatox (ABR-217620) is a chimeric protein with a T-cell-activating superantigen fused to the Fab of an antibody targeting the 5T4 tumor antigen, which may lead to T-cell activation and anti-tumor immune response (PMID: 24445502). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Naptumomab estafenatox | ABR-217620 | Naptumomab estafenatox (ABR-217620) is a chimeric protein with a T-cell-activating superantigen fused to the Fab of an antibody targeting the 5T4 tumor antigen, which may lead to T-cell activation and anti-tumor immune response (PMID: 24445502). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|